IGC logo

IGC
IGC Pharma Inc

30,093
Mkt Cap
$33.31M
Volume
420,147.00
52W High
$0.4985
52W Low
$0.242
PE Ratio
-5.46
IGC Fundamentals
Price
$0.3372
Prev Close
$0.3397
Open
$0.34
50D MA
$0.2846
Beta
0.59
Avg. Volume
306,519.05
EPS (Annual)
-$0.0931
P/B
4.32
Rev/Employee
$18,157.14
$21.64
Loading...
Loading...
News
all
press releases
TLRY, CGC, ACB, MSOS Pare Early Gains After Marijuana Reclassification: Retail Says ‘Weed Industry Is Reborn’
The U.S. Department of Justice formally moved to reclassify state-licensed medical marijuana as a less dangerous drug, four months after President Donald Trump signed an executive order.
Stocktwits·3d ago
News Placeholder
More News
News Placeholder
TLRY, CGC, IGC Stocks Light Up On Trump Pot Reclassification Hopes This Week
Axios reported on Wednesday, citing an administration official, that the Trump administration is slated to reclassify marijuana as soon as Wednesday.
Stocktwits·4d ago
News Placeholder
electroCore, Inc. (ECOR) Reports Q4 Loss, Lags Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of +1.45% and -0.18%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·1mo ago
News Placeholder
Merck KGaA (MKKGY) Lags Q4 Earnings Estimates
Merck KGaA (MKKGY) delivered earnings and revenue surprises of -40.43% and +0.69%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
IGC Pharma, Inc. (IGC) Reports Q2 Loss, Misses Revenue Estimates
IGC Pharma, Inc. (IGC) delivered earnings and revenue surprises of 0.00% and -56.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Profound Medical (PROF) Reports Q3 Loss, Tops Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of +31.58% and +0.74%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of +43.48% and -77.27%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5mo ago
News Placeholder
Theravance Biopharma (TBPH) Q3 Earnings and Revenues Beat Estimates
Theravance Bio (TBPH) delivered earnings and revenue surprises of +233.33% and +2.08%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
<
1
2
...
>

Latest IGC News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.